Study biomarker testing in metastatic leiomyosarcoma
Part of Cancer clinical trials.
This trial looks at lab markers (biomarkers) in tumor samples from people with leiomyosarcoma that has spread or can’t be fully removed. It also enrolls people who are receiving certain first-line chemotherapy, and your results may help guide future treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have leiomyosarcoma (LMS) that is metastatic or unresectable (can’t be fully removed with surgery).
- You are starting first-line chemotherapy with doxorubicin-based treatment or gemcitabine/docetaxel.
- You have measurable tumor spots on scans (target lesions) that meet the trial’s measurement rules.
- If you can, you provide stored tumor tissue from a past biopsy/surgery for research testing (slides and/or tissue).
- No age limit is listed, so adults and children may be eligible if other criteria fit.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a combination of three anti-cancer medicines to shrink or control leiomyosarcoma that cannot be fully removed by surgery or has spread. It may help people whose cancer has grown after prior treatment.
This study looks at lab biomarkers (signs in tumor tissue) in people with localized leiomyosarcoma. It also requires treatment with chemotherapy before surgery to see if the information from tumor samples can help guide care.
This trial tests a combination of two drugs—all-trans retinoic acid (ATRA, a vitamin A derivative) and cemiplimab (an immunotherapy)—for people with advanced leiomyosarcoma who've already had chemotherapy. The goal is to see if this combination can shrink tumors or slow cancer growth.
This trial tests a new immunotherapy drug called ivonescimab in people with leiomyosarcoma (a rare soft-tissue cancer) that cannot be surgically removed or has spread. The drug works by helping your immune system recognize and fight cancer cells.
This study looks at how people think about and respond to genetic testing for a specific genetic change found in sarcoma (a type of cancer). It aims to understand beliefs and attitudes toward this testing.
This study tests a new drug called REC-617 in patients with a rare muscle cancer (leiomyosarcoma) that has spread or cannot be surgically removed. The drug targets cancer cells that lack a specific protein called RB1, and you must have already tried at least one other cancer treatment before joining.
Hear when a new Leiomyosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.